Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 10/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.57 |
| ▸ | MMP2 | P08253 | 9/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.50 |
| ▸ | MMP3 | P08254 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365985 | 0.84 | ADAM10 (0.69) | ADAM10ERBB2MMP2SIGMAR1MMP3 | |
| SCHEMBL1364073 | 0.84 | ADAM10 (0.69) | ADAM10ERBB2MMP2SIGMAR1MMP3 | |
| SCHEMBL1365255 | 0.77 | ADAM10 (0.59) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL1364026 | 0.77 | ADAM10 (0.59) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL17309088 | 0.76 | ADAM10 (0.59) | ADAM10ERBB2MMP2SIGMAR1MMP3 | |
| SCHEMBL6023055 | 0.72 | ADAM10 (1.00) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL1366383 | 0.72 | ADAM10 (1.00) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL206346 | 0.72 | ADAM10 (1.00) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL1363898 | 0.72 | ADAM10 (1.00) | ADAM10ERBB2MMP2MMP3MMP9 | |
| SCHEMBL28961218 | 0.71 | SIGMAR1 (0.63) | ADAM10ERBB2MMP2SIGMAR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | claimed |
| EP-2637679-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | The University of Chicago (US) | 2013-09-18 | — | — | EP | claimed |
| WO-2012064865-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | THE UNIVERSITY OF CHICAGO (US) | 2012-05-18 | — | — | WO | claimed |
| US-9345677-B2 | Compositions, methods and kits relating to HER-2 cleavage | INCYTE CORPORATION (US) | 2016-05-24 | — | — | US | disclosed |
| US-9150865-B2 | Role of ADAM10 and its relevance to disease and therapeutics | THE UNIVERSITY OF CHICAGO (US) | 2015-10-06 | — | — | US | disclosed |
| EP-1613269-B1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORP (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | UNIVERSITY OF CHICAGO (US) | 2014-06-26 | — | — | US | disclosed |
| EP-2637679-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | The University of Chicago (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20120263676-A1 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-10-18 | — | — | US | disclosed |
| WO-2012064865-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | THE UNIVERSITY OF CHICAGO (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8088737-B2 | Treating a cancer, in particular breast cancer, that overexpresses Her-2 by administering an ADAM inhibitor; novel variants of ADAM15 and ADAM15; synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1613269-A2 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | Incyte Corporation (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20040247602-A1 | Compositions, methods and kits relating to Her-2 cleavage | INCYTE CORPORATION | 2004-12-09 | — | — | US | disclosed |
| WO-2004089294-A2 | COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE | INCYTE CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178399-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | ADAM10, ADAM8, ADAM17 | ADAM10 1/4885ERBB2 2355/4885MMP2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.